HONG KONG – Takeda Pharmaceutical Co.’s ambitions to expand in the lucrative U.S. health care market led the drugmaker to begin a painstaking examination of Shire PLC’s assets more than two years prior to striking a $62 billion deal.
In particular, Shire’s neuroscience unit and its gastrointestinal products sparked Takeda’s interest. One hurdle, though, gave them pause: the steep purchase price.
Unable to view this article?
This could be due to a conflict with your ad-blocking or security software.
Please add japantimes.co.jp and piano.io to your list of allowed sites.
If this does not resolve the issue or you are unable to add the domains to your allowlist, please see out this support page.
We humbly apologize for the inconvenience.